M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

Phase 2

Active, not recruiting

Conditions: Malignant Neoplasms of Female Genital Organs
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cancer

Interventions: Drug: Bevacizumab

First Posted Date: 2016-08-31

Last Posted Date: 2025-02-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT02884648

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

FDG PET Imaging in Diagnosing Patients With Glioblastoma

Early Phase 1

Completed

Conditions: Brain Glioblastoma

Interventions: Procedure: Computed Tomography
Radiation: Fludeoxyglucose F-18
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2016-08-31

Last Posted Date: 2022-07-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT02885272

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Oxidative Phosphorylation Inhibitor IACS-010759
Other: Pharmacological Study

First Posted Date: 2016-08-29

Last Posted Date: 2023-06-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT02882321

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

Phase 2

Active, not recruiting

Conditions: Oral Cavity Carcinoma
Oral Intraepithelial Neoplasia

Interventions: Other: Laboratory Biomarker Analysis
Other: Patient Observation
Biological: Pembrolizumab

First Posted Date: 2016-08-29

Last Posted Date: 2025-01-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT02882282

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury

Phase 2

Withdrawn

Conditions: Drug-Induced Nephropathy
Hypertension
Proteinuria

Interventions: Dietary Supplement: Arginine
Drug: Placebo

First Posted Date: 2016-08-29

Last Posted Date: 2019-05-21

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02882373

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma

Interventions: Biological: Blinatumomab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Biological: Inotuzumab Ozogamicin
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Drug: Methotrexate
Biological: Ofatumumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2016-08-24

Last Posted Date: 2025-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT02877303

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer

Conditions: Colorectal Cancer

Interventions: Procedure: Endoscopy

First Posted Date: 2016-08-24

Last Posted Date: 2019-05-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 250

Registration Number: NCT02877056

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Carcinoma
Breast Lump
Edema
Erythema
Estrogen Receptor Negative
HER2/Neu Negative
Inflammatory Breast Carcinoma
Invasive Breast Carcinoma
Peau d'Orange
Progesterone Receptor Negative

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Biological: Panitumumab

First Posted Date: 2016-08-23

Last Posted Date: 2025-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT02876107

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer

Active, not recruiting

Conditions: Locally Advanced Rectal Adenocarcinoma
Metastatic Rectal Adenocarcinoma
Rectosigmoid Adenocarcinoma
Recurrent Rectal Adenocarcinoma
Recurrent Rectosigmoid Carcinoma
Stage III Rectal Cancer AJCC v8
Stage IIIA Rectal Cancer AJCC v8
Stage IIIB Rectal Cancer AJCC v8
Stage IIIC Rectal Cancer AJCC v8
Stage IV Rectal Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection

First Posted Date: 2016-08-22

Last Posted Date: 2025-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 341

Registration Number: NCT02874885

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Phase 2

Completed

Conditions: Ann Arbor Stage II Grade 2 Follicular Lymphoma
Ann Arbor Stage III Grade 2 Follicular Lymphoma
Fever
Bulky Disease
Night Sweats
Ann Arbor Stage II Grade 1 Follicular Lymphoma
Ann Arbor Stage IV Grade 2 Follicular Lymphoma
Fatigue
Weight Loss
Ann Arbor Stage IV Grade 1 Follicular Lymphoma

Interventions: Drug: Lenalidomide
Biological: Obinutuzumab

First Posted Date: 2016-08-18

Last Posted Date: 2025-06-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 96

Registration Number: NCT02871219

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy